ACTU — ACTUATE THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1652935 ·
Last close
$0.68
Market Cap
$16.33M
52W High
$8.49
52W Low
$0.61
ADV30
405,167
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,906,588 | -4,866,635 | 5,199,339 | 4,425,841 | 4,210,187 |
| Mar 2026 | 0 | — | -5,705,956 | -5,625,749 | 8,911,286 | 8,134,004 | 5,126,888 |
| Dec 2025 | 0 | — | -4,688,473 | -4,553,953 | 14,035,910 | 13,159,423 | 6,111,907 |
| Sep 2025 | 0 | — | -5,472,378 | -5,407,470 | 17,713,934 | 16,924,763 | 6,777,653 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,604,840
Investing CF
—
Financing CF
$23,849,439
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.11
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-160,233,450
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-21,516,328
Pretax Income TTM
$-21,536,577
Interest Exp TTM
$20,249
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -22,495,312 | -22,227,852 | 14,035,910 | 6,111,907 | 7,924,003 | -19,206,253 |
| Dec 2024 | 0 | -25,160,734 | -27,285,328 | 9,318,448 | 9,214,262 | 104,186 | -21,842,648 |
| Dec 2023 | 0 | -24,973,829 | -24,744,620 | 2,995,566 | 102,622,079 | -99,626,513 | -21,625,167 |
| Dec 2022 | 0 | -20,206,807 | -20,159,401 | 20,483,056 | 95,788,488 | -75,305,432 | -17,794,093 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALLR | Allarity Therapeutics, Inc. | $16.39M | $1.03 | — |
| KTTA | Pasithea Therapeutics Corp. | $16.67M | $0.50 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $15.90M | $0.58 | — |
| CMMB | Chemomab Therapeutics Ltd. | $15.83M | $2.16 | — |
| TVRD | Tvardi Therapeutics, Inc. | $16.94M | $1.27 | — |
News headlines (Yahoo Finance, 1h cache)
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 21:00 · Yahoo
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
2026-09-09 11:00 · Yahoo
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
2026-06-09 11:45 · Yahoo
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
2026-06-01 11:00 · Yahoo
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
2026-05-11 11:00 · Yahoo
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
2026-05-06 12:45 · Yahoo
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancr
2026-04-14 12:45 · Yahoo
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
2026-03-24 11:00 · Yahoo
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
2026-03-09 12:45 · Yahoo
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
2026-03-04 22:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.